ALDX
Aldeyra Therapeutics, Inc.
$1.73
+0.00%
2026-05-08
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Key Fundamentals
Forward P/E
-6.83
EPS (TTM)
$-0.56
ROE
-58.7%
Profit Margin
0.0%
Debt/Equity
35.10
Price/Book
2.39
Beta
1.15
Market Cap
$106.2M
Avg Volume (10D)
967K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$5.74
60D Low
$1.07
Avg Volume
3.1M
Latest Close
$1.73
Get breakout alerts for ALDX
Sign up for Breakout Scanner to receive daily notifications when ALDX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Aldeyra Therapeutics, Inc. (ALDX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ALDX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ALDX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.